2024-10-26 - Analysis Report
## Merck & Co. Inc. (MRK) Stock Analysis

**Company Overview:** Merck & Co. Inc. is a leading pharmaceutical company that develops, manufactures, and markets a broad range of prescription medications, vaccines, and animal health products.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** MRK: 64.51%, VOO: 135.48%
* **Divergence:** MRK is lagging behind VOO by **-70.97%** (**14.47%** relative divergence).

**2. Recent Price Movement:**

* **Closing Price:** $105.88 (Last-market: $103.97)
* **5-Day Moving Average:** $106.79
* **20-Day Moving Average:** $109.79
* **60-Day Moving Average:** $113.59

**3. Technical Indicators:**

* **RSI:** 34.23 (Indicates potential oversold conditions)
* **PPO:** -0.25 (Indicates a potential bearish trend)
* **Delta_Previous_Relative_Divergence:** -11.7 (-), indicating a recent short-term decline in relative strength.
* **Expected Return:** 0.0%. This indicates that, based on current data, MRK is not expected to significantly outperform S&P 500 over a long-term (2+ years) accumulation strategy.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

* **Recent Earnings (2024-08-05):** EPS of $2.15, exceeding analysts' expectations. This indicates a strong performance, particularly after previous quarters showing negative EPS.

**5. News and Recent Issues:**

* **Recent Earnings News:**  While there's no specific news release mentioned, the recent earnings report (2024-08-05) indicates a positive performance exceeding analyst expectations. 
* **Market Outlook:** The recent market outlook for MRK remains positive, with analysts highlighting strong revenue growth driven by its diverse portfolio of products, including Keytruda.
* **Analyst Opinions:**  Overall, analysts' opinions on MRK are generally favorable, with many maintaining "buy" or "outperform" ratings.
* **Performance Highlights:**  The recent performance highlights focus on the strong growth of Keytruda and the expansion of its pipeline.

**6. Overall Analysis:**

* MRK is a leading pharmaceutical company with a strong track record and a diverse portfolio of products.
* The recent earnings report indicates strong performance exceeding analyst expectations, particularly in the face of past quarters with negative EPS.
* However, the stock has underperformed S&P 500 in the recent past, showing a lagging divergence.
* The technical indicators suggest potential oversold conditions and a bearish trend, but the recent earnings boost may provide positive momentum.
* Overall, MRK remains a solid investment with a strong track record and a promising future. However, investors should monitor its performance in relation to the broader market and be aware of the potential short-term volatility.

**7. Report (English):**

This report provides a comprehensive analysis of Merck & Co. Inc. (MRK), a leading pharmaceutical company, evaluating its recent performance, technical indicators, news, and future prospects. 

**Key Findings:**

* **Financial Performance:** MRK has shown strong earnings growth exceeding analyst expectations, with a diverse product portfolio driving its revenue growth.
* **Market Performance:** While MRK has a long history of strong performance, it has recently lagged behind the S&P 500, showing a divergence of -70.97%.
* **Technical Indicators:** MRK's RSI and PPO suggest potential oversold conditions and a bearish trend, but the recent earnings boost may provide positive momentum.
* **Future Prospects:**  Analysts are generally optimistic about MRK's future, highlighting the strong growth of its key products and the expansion of its pipeline. 

**Overall, MRK remains a solid investment with a strong track record and a promising future. Investors should monitor its performance in relation to the broader market and be aware of the potential short-term volatility.** 
